RAB11A and cancer: It is possible that selective inhibition of Rab11a‐exosome biogenesis by interfering with accessory ESCRT‐III function in such tumours could block adaptive responses without preventing other important events, such as the ubiquitin‐mediated degradation of growth factor receptors in cancer cells.